In the ALINA trial adjuvant alectinib (a second-generation ALK TKI) for 24 months is compared with adjuvant platinum-based chemotherapy after surgical resection in patients with ALK-positive stage IB-IIIA NSCLC (NCT03456076) [53]. This evidence concerns the gene ALK and non-small cell lung carcinoma.